In addition, cyclin-dependent protein kinase 9 (CDK9) is a druggable target for prostate cancer because CDK9 can not only phosphorylate AR and activate AR transcriptional activity but also target anti-apoptotic proteins [82]. Here, AR is linked to prostate carcinoma.